Salvage chemotherapy regimens in relapsed or refractory Hodgkin lymphoma.
Regimen . | No. of patients . | CR,% 95% CI . | PR,% 95% CI . | ORR, % 95% CI . | Grade 3/4 NEUT, % . | Grade 3/4 TCP, % . | Grade 3/4 VOM, % . | Toxic deaths, % 95% CI . |
---|---|---|---|---|---|---|---|---|
*mucositis reported in 9% | ||||||||
†all patients experience grade IV neutropenia | ||||||||
‡5% toxic death rate included patients undergoing ASCT | ||||||||
Chemotherapy regimens: BEAM, BCNU, etoposide, ara-C, melphalan; ICE, ifosfamide, carboplatin, etoposide, DHAP, dexamethasone, ara-C, cisplatin; GDP, gemcitabine, dexamethasone, cisplatin; GVD, gemcitabine, vinorelbine, doxil (liposomal doxorubicin); IEV, ifosfamide, etoposide, vinorelbine; MINE, mitoguazone, ifosfamide, vinorelbine, etoposide; IV, ifosfamide, vinorelbine. | ||||||||
NS indicates not stated; NEUT, neutropenia, TCP, thrombocytopenia; VOM, vomiting | ||||||||
Dexa-BEAM22 | 144 | 27 | 54 | 81 | NS | NS | NS | 5 |
20–34 | 46–62 | 75–87 | 1–9 | |||||
Mini-BEAM25 | 55 | 49 | 33 | 82 | 86 | 60 | NS | 2 |
35–63 | 21–47 | 69–91 | 0.1–10 | |||||
ICE67 | 65 | 26 | 59 | 85 | NS | NS | NS | 0 |
16–39 | 46–71 | 74–92 | 0–5 | |||||
DHAP q2wk28 | 102 | 21 | 68 | 89 | 88 | 69 | 26 | 0 |
13–29 | 59–77 | 83–95 | 0–4 | |||||
GDP29 | 23 | 17 | 52 | 69 | 9 | 13 | 13 | 0 |
5–39 | 31–73 | 47–87 | 0–15 | |||||
GVD*68 | 91 | 19 | 51 | 70 | 63 | 14 | 0 | 0 |
IEV32 | 51 | 76 | 84 | 100† | NS | NS | 0 | |
60–88 | 71–93 | |||||||
MINE31 | 157 | NS | NS | 75 | NS | NS | NS | 5 |
64–84 | ||||||||
IV33,69 | 47 | 45 | 38 | 83 | 65 | 0 | 2 | NS |
30–60 | 25–54 | 69–92 |
Regimen . | No. of patients . | CR,% 95% CI . | PR,% 95% CI . | ORR, % 95% CI . | Grade 3/4 NEUT, % . | Grade 3/4 TCP, % . | Grade 3/4 VOM, % . | Toxic deaths, % 95% CI . |
---|---|---|---|---|---|---|---|---|
*mucositis reported in 9% | ||||||||
†all patients experience grade IV neutropenia | ||||||||
‡5% toxic death rate included patients undergoing ASCT | ||||||||
Chemotherapy regimens: BEAM, BCNU, etoposide, ara-C, melphalan; ICE, ifosfamide, carboplatin, etoposide, DHAP, dexamethasone, ara-C, cisplatin; GDP, gemcitabine, dexamethasone, cisplatin; GVD, gemcitabine, vinorelbine, doxil (liposomal doxorubicin); IEV, ifosfamide, etoposide, vinorelbine; MINE, mitoguazone, ifosfamide, vinorelbine, etoposide; IV, ifosfamide, vinorelbine. | ||||||||
NS indicates not stated; NEUT, neutropenia, TCP, thrombocytopenia; VOM, vomiting | ||||||||
Dexa-BEAM22 | 144 | 27 | 54 | 81 | NS | NS | NS | 5 |
20–34 | 46–62 | 75–87 | 1–9 | |||||
Mini-BEAM25 | 55 | 49 | 33 | 82 | 86 | 60 | NS | 2 |
35–63 | 21–47 | 69–91 | 0.1–10 | |||||
ICE67 | 65 | 26 | 59 | 85 | NS | NS | NS | 0 |
16–39 | 46–71 | 74–92 | 0–5 | |||||
DHAP q2wk28 | 102 | 21 | 68 | 89 | 88 | 69 | 26 | 0 |
13–29 | 59–77 | 83–95 | 0–4 | |||||
GDP29 | 23 | 17 | 52 | 69 | 9 | 13 | 13 | 0 |
5–39 | 31–73 | 47–87 | 0–15 | |||||
GVD*68 | 91 | 19 | 51 | 70 | 63 | 14 | 0 | 0 |
IEV32 | 51 | 76 | 84 | 100† | NS | NS | 0 | |
60–88 | 71–93 | |||||||
MINE31 | 157 | NS | NS | 75 | NS | NS | NS | 5 |
64–84 | ||||||||
IV33,69 | 47 | 45 | 38 | 83 | 65 | 0 | 2 | NS |
30–60 | 25–54 | 69–92 |